26 jul: USA/aktier: Optimismen bobler
26 jul: Torsdagens obligationer: Spanien fik tiltrængt åndedrag
26-07-2012 16:24:00

UPDATE: United Tech 2nd Quarter Net Rises 0.8%, Cuts View

Relateret indhold
Relateret debat
15 apr - 
Jeg synes selv, at markedet for børsnoterede aktier er ..
14 apr - 
Det er et super luk vi får. Ikke for meget op, for så s..
14 apr - 
Ja de syndikat drenge er nogen vaerre nogen

--United Tech receives regulatory clearance on its acquisition of Goodrich Corp.

--United Tech second-quarter profit rose 0.8% amid a revenue decline

--Company cuts its full-year outlook on slowing global economy and late July close for Goodrich

(Updates with details on the regulatory clearance of the Goodrich deal.)

By Victoria Stilwell

United Technologies Corp.'s (UTX) second-quarter profit edged up 0.8% and the company cut its full-year guidance, while the company said it received all regulatory approval related its $16.5 billion deal to acquire aircraft-components maker Goodrich Corp. (GR).

The industrial conglomerate said the acquisition, initially announced on Sept. 21, is expected to close by the end of the week after Thursday's conclusion of the regulatory review by the U.S. Department of Justice and the European Commission.

The regulatory clearance requires United Tech to sell Goodrich's electric power systems business and its pumps and engine controls business. The company will also sell Goodrich's interest in Aero Engine Controls, a joint venture with Rolls-Royce Holdings PLC (RR.LN). Although the AEC aftermarket business will stay with United Tech, Rolls Royce will have the ability to purchase the business in the future.

The Justice Department is also requiring that United Tech extend the term of certain contracts held by customers of Goodrich's engine control systems business for 30 days after its divestiture and provide supply and transition services agreements to the buyers of divested assets to help them fulfill the obligations of the businesses.

The department said that left alone, the acquisition would have resulted in higher prices, less favorable contractual terms and less innovation in aircraft components.

United Tech lowered its full-year guidance in light of the slowing global economy and late-July close for Goodrich, now expecting sales of $58 billion to $59 billion and per-share earnings of $5.25 to $5.35. The company previously predicted sales of $61 billion to $62 billion on earnings of $5.30 to $5.50 a share. The company also said it will increase its investment on restructuring to $500 million from $450 million.

For the second quarter, United Technologies reported a profit of $1.33 billion, or $1.47 a share, fractionally up from a year-earlier profit of $1.32 billion, or $1.44 a share. The company's per-share earnings from continuing operations rose to $1.62 from $1.41 a year earlier.

The latest period included 10 cents a share of favorable one-time items, partially offset by 6 cents in restructuring costs. The year-earlier period included a currency translation gain of 6 cents.

Revenue declined 4.6% to $13.81 billion.

Analysts surveyed by Thomson Reuters recently expected a per-share profit of $1.41 on revenue of $14.45 billion.

Revenue from Pratt & Whitney rose 5.2% as profit edged up 0.7%, while revenue at the Otis unit decreased 5.2% and profit fell 12%.

Total costs and expenses dropped 4.5% to $12 billion.

Shares were recently up 2.6% at $74.40.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 10:24 ET (14:24 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Arkil-konsortium taber kontrakt hos Banedanmark

23-05-2016 15:29:01
Banedanmark har mandag ophævet kontrakten med konsortiet Strukton Rail om sporombygningsarbejde på Østfyn efter problemerne med togdriften i Kristi himmelfarts-..

Genmab får kræfthåb godkendt i Europa - NY

23-05-2016 13:15:30
Biotekselskabet Genmab kan nu også begynde at sælge kræftmidlet Darzalex på det europæiske marked, da EU-Kommissionen har givet midlet markedsføringstilladelse...

Vestas-fabrik i Lem har fået 14 påbud over tre år - NY

23-05-2016 11:38:53
INFO: Arbejdstilsynet har opdateret tallene i citatet fra Anders Just PedersenArbejdstilsynet har besøgt Vestas' vingefabrik i Lem 26 gange siden 2013, og det h..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab får kræfthåb godkendt i Europa - NY
2
Bavarian opnår positive resultater med vaccine mod RS-virus -NY
3
Aktier/tendens: Investorerne kan skimte små plusser fra start
4
NNIT-aktien fortsætter frem efter stor Pandora-aftale
5
Aktier/åbning: Genmab fortsætter frem med kurs mod rekord

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2016 08:03:05
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160517.1 - EUROWEB6 - 2016-05-24 08:03:05 - 2016-05-24 08:03:05 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x